Purper-Ouakil D, Blasco-Fontecilla H, Ros T, et al. - For the treatment of attention-deficit hyperactivity disorder (ADHD), one of the promising interventions is neurofeedback. In NEWROFEED, a prospective, multicentre, randomized (3:2), reference drug-controlled trial, researchers assessed the noninferiority of personalized at-home neurofeedback (NF) training vs methylphenidate in the treatment of children with ADHD. The NF group comprised 111 children and underwent eight visits and two therapeutic phases of 16 to 20 at-home sessions with down-training of the theta/beta ratio (TBR) for children with high TBR and elevating the sensorimotor rhythm (SMR) for the others. The control group comprised 67 children and received optimally titrated long-acting methylphenidate. Clinicians’ reports suggest inferiority of the effects of at-home NF vs those of methylphenidate as a stand-alone treatment. Significant pre–post improvements in core ADHD symptoms and in a broader range of problems occurred in both the treatment groups.